Viracta Therapeutics
Yahoo Finance • last year
Viracta Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
Reported preliminary clinical data from the pivotal NAVAL-1 clinical trial of Nana-val in patients with relapsed or refractory EBV+ peripheral T-cell lymphoma showing an overall response rate and complete response rate of 40% Reported int... Full story
Yahoo Finance • last year
Viracta Therapeutics to Present at Upcoming Investor Conferences
SAN DIEGO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today... Full story
Yahoo Finance • last year
Viracta Therapeutics to Host R&D Day Highlighting Nana-val in Epstein-Barr Virus (EBV)-Associated Cancers
Preliminary clinical data from patients with relapsed/refractory EBV+ peripheral T-cell lymphoma in the pivotal NAVAL-1 trial demonstrated overall and complete response rates of 40%; follow-up from the Phase 1b/2 study demonstrated median... Full story
Yahoo Finance • last year
Viracta Therapeutics to Host R&D Day on October 4, 2023
SAN DIEGO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, toda... Full story
Yahoo Finance • last year
Viracta Therapeutics Announces New Employment Inducement Grant
SAN DIEGO, Aug. 18, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today... Full story
Yahoo Finance • last year
Viracta Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
Achieved efficacy threshold to advance Epstein-Barr virus-positive (EBV+) peripheral T-cell lymphoma into Stage 2 becoming the leading indication in pivotal NAVAL-1 study of Nana-val Prioritized EBV+ diffuse large B-cell lymphoma and EBV+... Full story
Yahoo Finance • last year
Viracta Therapeutics’ Pivotal NAVAL-1 Trial Achieves Efficacy Threshold for Expansion in Relapsed or Refractory EBV-positive Peripheral T-Cell Lymphoma (R/R EBV+ PTCL)
SAN DIEGO, June 28, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that... Full story
Yahoo Finance • 2 years ago
Viracta Therapeutics to Present at the Stifel 2023 Targeted Oncology Days
SAN DIEGO, April 19, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced tha... Full story
Yahoo Finance • 2 years ago
Viracta Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update
Pivotal NAVAL-1 study of Nana-val in Epstein-Barr virus-positive (EBV+) lymphoma open at 70 sites globally; update on first lymphoma subtype that may advance from Stage 1 to Stage 2 expected in the first half of 2023 Completed initial enr... Full story
Yahoo Finance • 2 years ago
Viracta Therapeutics to Present at the 33rd Annual Oppenheimer Healthcare Conference
SAN DIEGO, March 08, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced tha... Full story
Yahoo Finance • 2 years ago
Viracta Therapeutics to Present at the 2023 SVB Securities Global Biopharma Conference
SAN DIEGO, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that... Full story
Yahoo Finance • 2 years ago
Viracta Therapeutics Announces Orphan Drug Designation Granted by the European Commission to Nana-val for the Treatment of Diffuse Large B-cell Lymphoma
SAN DIEGO, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that... Full story
Yahoo Finance • 2 years ago
Viracta Therapeutics Announces First Clinical Response in Epstein-Barr Virus-Positive (EBV+) Solid Tumor Setting and Outlines Key 2023 Clinical Objectives
Partial response (PR) observed in third dose level of the Phase 1b dose escalation study of Nana-val in EBV+ recurrent/metastatic (R/M)nasopharyngeal carcinoma (NPC); enrollment into forth dose level is ongoing Anticipates clinical progra... Full story
Yahoo Finance • 2 years ago
Viracta Therapeutics Announces Preliminary Dose-Ranging Data from the Phase 1b/2 Trial of Nana-val in Advanced Epstein-Barr Virus-Positive (EBV+) Solid Tumors at the ESMO Immuno-Oncology Congress
SAN DIEGO, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today reported preli... Full story
Yahoo Finance • 2 years ago
Viracta Therapeutics Reports Third Quarter 2022 Financial Results and Provides Updates on Clinical Programs
Pivotal NAVAL-1 trial of Nana-val in Epstein-Barr virus-positive (EBV+) lymphoma open for enrollment at more than 50 sites worldwide; update on the first indication that may advance from Stage 1 to Stage 2 now anticipated in the first half... Full story
Yahoo Finance • 3 years ago
Enlivex Appoints Dr. Roger J. Pomerantz to its Board of Directors as Vice Chairman
Former Worldwide Head of Licensing and Acquisition and Knowledge Management at Merck & Co., where he led the completion of more than150 business development transactions Former Global Head of Infectious Diseases for Johnson & Johnson Pharm... Full story
Yahoo Finance • 3 years ago
Viracta Therapeutics to Present at Upcoming May Investor Conferences
SAN DIEGO, May 11, 2022 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that company management will present and participate in one-on-one mee... Full story
Yahoo Finance • 3 years ago
Viracta Therapeutics Reports First Quarter 2022 Financial Results and Recent Updates
Continued global expansion of NAVAL-1, the pivotal trial of Nana-val for the treatment of Epstein-Barr virus-positive (EBV+) lymphoma; update on the initial cohort(s) that have advanced into Stage 2 anticipated in the second half of 2022... Full story
